𝔖 Bobbio Scriptorium
✦   LIBER   ✦

FEZ1/LZTS1 protein expression in ovarian cancer

✍ Scribed by Daniela Califano; Sandro Pignata; Carmela Pisano; Stefano Greggi; Giuseppe Laurelli; Nunzia Simona Losito; Alessandro Ottaiano; Adolfo Gallipoli; Rosa Pasquinelli; Veronica De Simone; Roberto Cirombella; Alfredo Fusco; Gennaro Chiappetta

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
300 KB
Volume
222
Category
Article
ISSN
0021-9541

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The FEZ1/LZTS1 (FEZ1) gene maps to chromosome 8p22 and is frequently altered in human cancer. FEZ1 has been proposed as a candidate tumour suppressor gene and its loss may contribute to tumour progression. We have analysed the expression of FEZ1 protein in tissues from ovarian carcinomas in relation to clinico‐pathological variables, response to chemotherapy and disease‐free and overall survival. FEZ1 status was assessed by immunohistochemistry. Cytoplasmic staining for FEZ1 protein was absent or drastically reduced in 38% of tumours. FEZ1 protein expression was not related to tumour grade, histotype, disease‐free survival, or overall survival. On the contrary, it was significantly correlated with age and with FIGO stage of disease. This finding indicates that FEZ1 is involved in ovarian carcinogenesis. Moreover, loss of FEZ1 protein significantly predicted a complete treatment response in patients who received taxane‐based chemotherapy. In conclusion, the reduction or loss of FEZ1 protein could be an aid to the clinical management of patients affected by ovarian carcinoma. J. Cell. Physiol. 222: 382–386, 2010. © 2009 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Selenium binding protein 1 in ovarian ca
Selenium binding protein 1 in ovarian cancer
✍ Kuan-Chun Huang; Dong Choon Park; Shu-Kay Ng; Ji Young Lee; Xiaoyan Ni; Wing-Chu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 378 KB 👁 1 views

## Abstract Selenium binding protein 1 (SELENBP1) was identified to be the most significantly down‐regulated protein in ovarian cancer cells by a membrane proteome profiling analysis. SELENBP1 expression levels in 4 normal ovaries, 8 benign ovarian tumors, 12 borderline ovarian tumors and 141 invas

Expression of sperm protein 17 (Sp17) in
Expression of sperm protein 17 (Sp17) in ovarian cancer
✍ J. Michael Straughn Jr.; Denise R. Shaw; Antonio Guerrero; Snehal M. Bhoola; Ali 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 351 KB 👁 1 views

## Abstract Sperm protein 17 (Sp17) is an antigenic protein highly expressed in spermatozoa. Sp17 expression was demonstrated recently in multiple myeloma, suggesting that it may be a novel cancer‐testis antigen. Expression of Sp17 mRNA and protein was examined in human ovarian tumors. Sp17 mRNA wa

Peritoneal fluid from ovarian cancer pat
Peritoneal fluid from ovarian cancer patients stimulates MUC1 epithelial mucin expression in ovarian cancer cell lines
✍ David J. Munster; Rachel J. Quin; Amolak S. Bansal; Bruce G. Ward; Michael A. Mc 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 136 KB 👁 2 views

The MUC1 epithelial mucin is a transmembrane glycoprotein that is frequently but variably over-expressed by adenocarcinomas. It is used as a diagnostic serum tumour marker and is a candidate target for tumour immunotherapy. Peritoneal fluid (PF) samples from ovarian cancer patients were investigated

Expression of mitogen-activated protein
Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma
✍ Carsten Denkert; Wolfgang D. Schmitt; Stefan Berger; Angela Reles; Sören Pest; A 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 900 KB

## Abstract The mitogen‐activated protein kinase phosphatase‐1, MKP‐1 (CL100) is involved in inactivation of MAP‐kinase pathways, regulation of stress‐responses and suppression of apoptosis. We investigated expression of MKP‐1 in 90 cases of primary ovarian tumors, 11 normal ovaries as well as 4 ov